Dominique de Valeriola

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

M. Piccart, D. Strumberg, B. Schwartz, 2005, British Journal of Cancer.

Need for global action for cancer control.

R. J. Thomas, H. Bartelink, A. Gavin, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.

M. Piccart, J. Sculier, A. Awada, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers

M. Piccart, A. Awada, T. Gil, 2004, Anti-cancer drugs.

Adjuvant chemotherapy in 2005: standards and beyond.

M. Piccart, T. Čufer, E. de Azambuja, 2005, Breast.

EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.

L Biganzoli, M. Piccart, M. Nooij, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.

M. Piccart, E. W. Van Den Neste, S. Bartholomeus, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.